（社）東京血液疾患研究所（ＭＲＣ ＪＡＰＡＮ）は、国際ＭＤＳ財団に認定されたCenter of Excellenceです。
MRC JAPANは世界最先端の
骨髄異形成症候群（ＭＤＳ）の研究機関です。
論文（欧文症例報告・総説）Papers&Presentation
２, 欧文症例報告・総説
欧文症例報告
| ２０１１年 | |
| 1 | Ishii Y, Harada K, Kuroda R, Nagai H, Nakajima M, Saito N, Ogata K, Yoshida
K. Bilateral thalamic hemorrhage and intracranial injuries related to alcohol-induced thrombocytopenia. J Clin Pathol, 64, 1034-5, 2011 |
| ２００７年 | |
| 1 | Tamura H, Okamoto M, Yamashita T, Sato C, Watanabe A, Kondo A, Tatsuguchi A, Tsuji T, Ogata K, Dan K. Pure white cell aplasia: report of the first case associated with primary biliary cirrhosis. Int J Hematol 85, 97-100, 2007 |
| ２００６年 | |
| 1 | Yokose N, Shioi Y, Sugisaki Y, Ohaki Y, Ogata K, Dan K. CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-). Leuk Lymphoma 47, 1415-1417, 2006 |
| 2 | Shoda T, Yoshimura M, Hayata D, Miyazawa Y, Ogata K. Marked spherocytosis in clostridal sepsis. Int J Hematol 83, 179-180, 2006 |
| ２００１年 | |
| 1 | Yokose N, Ogata K, Sugisaki Y, Mori S, Yamada T, An E, Dan K. CD20-positive T cell leukemia/lymphoma: case report and review of the literature.Ann Hematol 80, 372-375, 2001 |
| １９９８年 | |
| 1 | Luo SS, Tamura H, Yokose N, Ogata K, Dan K. F ailure to detect anti-HTLV-1 antibody in a patient with adult T-cell leukaemia/lymphoma. Br J Haematol 103, 1207-1208, 1998 |
| 2 | Tamura H, Ogata K, Mori S, An E, Tajika K, Sugisaki Y, Dan K. Lymphoblastic lymphoma of natural killer cell origin, presenting as pancreatic tumour. Histopathology 32, 508-511, 1998 |
| １９９６年 | |
| 1 | Tamura H, Ogata K, Yokose N, An E, Kamikubo K, Dan K, Kajii E, Nomura T. |
| １９９７年 | |
| 1 | Yokose N, Ogata K, Nakamura K, Kamikubo K, Tamura H, An E, Dan K, Nomura
T. Hypofibrinogenemia induced by prednisolone therapy in a patient with chronic lymphocytic leukemia complicated with autoimmune hemolytic anemia. Am J Hematol 55, 166-167, 1997 |
| １９９５年 | |
| 1 | Yokose N, Ogata K, An E, Tamura H, Kamikubo K, Dan K, Nomura T. Lineage-unrestricted hematologic response to granulocyte colony-stimulating factor in a patient with refractory anemia with excess blasts. Ann Hematol 70, 163-167, 1995 |
| １９９０年 | |
| 1 | Ogata K, Tanabe Y, Iwakiri K, Ito T, Yamada T, Dan K, Nomura T. Two cases of disseminated Trichosporon beigelii infection treated with combination antifungal therapy. Cancer 65, 2793-2795, 1990 |
欧文総説
| ２０１１年 | |
| 1 | Ogata K. Flow cytometry will be a routine tool in clinical practice in myelodysplastic syndromes: a real story. Leuk Res (Editorial) 35, 848? 849, 2011 |
| ２０１０年 | |
| 1 | Valent P, Orazi A, B?sche G, Schmitt-Gr?ff A, George TI, Sotlar K, Streubel B, Beham-Schmid C, Cerny-Reiterer S, Krieger O, van de Loosdrecht A, Kern W, Ogata K, Wimazal F, Csomor J, V?rkonyi J, Sperr WR, Werner M, Kreipe H, Horny HP. Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). Oncotarget 1, 483-96, 2010 |
| ２００８年 | |
| 1 | Ogata K. Diagnostic flow cytometry for low-grade myelodysplastic syndromes. Hematol Oncol 26, 193-198, 2008 |
| 2 | Wells DA, Ogata K. On flow cytometry in myelodysplastic syndromes, with caveats. Leuk Res (Editorial) 32, 209-210, 2008 |
| ２００６年 | |
| 1 | Ogata K. Myelodysplastic syndromes: recent progress in diagnosis and understanding of their pathophysiology. J Nippon Med Sch 73, 300-307, 2006 |
| ２００５年 | |
| 1 | Ogata K, Yoshida Y. Clinical implications of blast immunophenotypes in myelodysplastic syndromes.Leuk Lymphoma 46, 1269-1274, 2005 |
| ２００３年 | |
| 1 | Tamura H, Ogata K, Dong H, Chen L. Immunology of B7-H1 and its roles in human diseases. Int J Hematol 78, 321-328, 2003 |
| ２０００年 | |
| 1 | Ogata K, Tamura H. Thrombopoietin and myelodysplastic syndromes. Int J Hematol 72, 173-177, 2000 |
| １９９７年 | |
| 1 | Yokose N, Ogata K. Plasma soluble interleukin-2 receptors in patients with myelodysplastic syndromes. Leuk Lymphoma 28, 171-176, 1997 |
| １９９５年 | |
| 1 | Ogata K, Yokose N, Nomura T. Interleukin-2 therapy for myelodysplastic syndrome: does it work? Leuk Lymphoma 17, 411-415, 1995 |
| １９９３年 | |
| 1 | Ogata K, Nomura T. Application of low-dose etoposide therapy for myelodysplastic syndromes.Leuk Lymphoma 12, 35-39, 1993 |
Supported by
Supported by
（社）東京血液疾患研究所
（ＭＲＣ ＪＡＰＡＮ）
事務所
〒182-0001
東京都調布市緑ヶ丘１－４５－４６
クレナイビル３Ｆ
TEL 03-6750-4720
FAX 03-6750-1013
研究室
〒156-0052
東京都世田谷区経堂5-38-9
東京血液疾患診療所内 Ｂ１Ｆ
E-mail : info@MRCJAPAN.com